UroGenesys researchers discover new target antigen for prostate cancers

STEAP Antigen Provides Promising Route for New Therapies, PNAS Reports

Santa Monica, CA, December 7, 1999 - UroGenesys, Inc. today reported the discovery of a novel gene that provides a promising route for developing new therapies to treat prostate cancer. The studies, published today in the journal Proceedings of the National Academy of Sciences (PNAS), describe a novel cell-surface antigen called STEAP which is expressed at high levels on prostate cancers, but is rarely produced in non-prostate tissues. These results indicate that the STEAP molecule may have utility as a target for new prostate cancer therapies, as well as for improved diagnostic tools to help monitor progression of the disease.

"STEAP possesses several features that make it a promising target for new cancer treatments," said Aya Jakobovits, Ph.D., Vice President of Research and Chief Scientific Officer at UroGenesys and an author on the paper. "The antigen is expressed at high levels on prostate tumors throughout all stages of the disease, including metastatic tumors. Its prostate-specific expression suggests that drugs targeted to STEAP may have a favorable safety profile."

Dr. Jakobovits continued, "STEAP is also expressed in androgen-independent tumors, providing an avenue for treatment of cancers that have become resistant to conventional hormone ablation therapies. Its presence on the surface of prostate cancer cells makes the molecule suitable for a wide variety of therapeutic approaches, including antibodies, small molecules and vaccines."

"STEAP is the first antigen to emerge from UroGenesys' in-house discovery program," said Donald B. Rice, Ph.D., President and Chief Executive Officer of UroGenesys. "The discovery illustrates how our disease-focused genomics program positions UroGenesys to identify and advance the development of products that may lead to improved treatments for prostate and other cancers." Dr. Rice added that UroGenesys plan

Contact: Robert Gottlieb or Sharon Karlsberg
Feinstein Kean Healthcare

Page: 1 2 3

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. $7.5 Million grant to Yale researchers for role of viruses in cancer
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Joslin researchers clarify mechanisms for beta-cell formation
6. Virginia Tech researchers to release findings on Smith River Project
7. Molecular motor myosin VI moves hand over hand, researchers say
8. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
9. Emory researchers map structure of anti-cancer molecule
10. Leukemia stem cells identified by Stanford researchers
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:

(Date:8/27/2019)... ... August 27, 2019 , ... e3 ... to announce that it has partnered with Bertec, a leading manufacturer of force ... Balance Advantage systems, a full line of clinical systems for both assessment and ...
(Date:8/25/2019)... ... ... Sierra Instruments is pleased to announce that their redesigned website portal ( sierrainstruments.com ... redesigned entry to the site with both engineers and those new to flow instruments ... streamlined menus and simple access to resources and information on products and services. ...
(Date:8/21/2019)... ... 21, 2019 , ... AbSci, a revolutionary synthetic biology company ... of complex protein therapeutics, today announced the appointment of Fred Larimore, PhD, to ... Larimore brings more than 30 years of experience in biopharmaceutical manufacturing and process ...
Breaking Biology News(10 mins):
(Date:9/4/2019)... , ... September 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... Science & Technology will present at the upcoming Nordic Life Science Days ...
(Date:8/29/2019)... NEW CENTURY, Kan. (PRWEB) , ... August 28, ... ... baking innovation expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the ... cutting-edge science to solve today’s baking challenges from optimizing production efficiency to cost ...
(Date:8/27/2019)... ... August 27, 2019 , ... Modality Solutions , an ... promoted Consulting Engineer, Robert Battista, to Senior Consulting engineer. , In his new ... mentoring new engineers as well as the creation of additional business opportunities and ...
(Date:8/23/2019)... , ... August 22, 2019 , ... ... drug delivery modalities and is scheduled to broadcast 4Q/2019. Check your local listings ... state-of-the-art skin patches for generic drug delivery. Focusing on therapeutics for children and ...
Breaking Biology Technology:
Cached News: